Short answer
CE marking rests on the EU MDR, with certificates from EU Notified Bodies; UKCA rests on the UK Medical Devices Regulations 2002, still based on the old EU directives, with certificates from UK approved bodies. For software the biggest difference is classification: EU MDR Rule 11 puts most decision-support software in class IIa or higher, while UK MDR 2002 has no equivalent rule. Most of the technical file can serve both marks, but you need a classification analysis under each framework. CE marked devices can be placed on the GB market until 30 June 2030, and the government plans indefinite recognition; a UK Responsible Person and MHRA registration are needed either way.
1. Why UKCA and CE now rest on different rules
When the UK left the EU, the UKCA (UK Conformity Assessed) mark was introduced for Great Britain. For medical devices, the governing law is the UK Medical Devices Regulations 2002 (UK MDR 2002), which gave effect in UK law to the old EU directives (MDD, AIMDD and IVDD). The UKCA requirements are still based on the annexes of those directives, as modified for GB.
The EU, meanwhile, replaced the directives with the EU MDR (Regulation (EU) 2017/745) and the IVDR. So the two marks now sit on different generations of rules. The UK plans to narrow the gap: MHRA has said its planned pre-market regulations will bring the essential requirements into closer alignment with the EU, introduce UDI and change the classification of several device types — but those regulations are not yet in force. Recognition runs one way only: GB recognises CE marking (see below), while the EU does not recognise UKCA.
The EU MDR has applied in Northern Ireland since 26 May 2021. Products placed on the Northern Ireland market need CE marking (with the UKNI indication where a UK notified body performed the assessment); UKCA is not recognised there. If your distribution includes NI, your CE obligations remain regardless of your UKCA status.
2. Requirements side by side
The table below covers the differences that matter most for medical software companies.
| Area | CE marking (EU MDR) | UKCA (UK MDR 2002) |
|---|---|---|
| Legal basis | Regulation (EU) 2017/745 | UK MDR 2002 (as amended), based on the former EU directives |
| Classification of software | Annex VIII Rule 11: software that provides information used for diagnostic or therapeutic decisions is at least Class IIa | Directive-based rules with no software-specific rule; much standalone software ends up in Class I |
| Conformity assessment body | EU notified body designated under the MDR (52 at the time of the Commission's February 2026 survey) | UK approved body; UK approved bodies cannot carry out CE assessments |
| When a third party is needed | Class IIa, IIb, III — and sterile, measuring or reusable surgical aspects of Class I | Class IIa, IIb, III — and sterile or measuring aspects of Class I |
| Representative for foreign manufacturers | EU authorised representative | UK Responsible Person — required for all non-UK manufacturers placing devices in GB, including with CE marking |
| Registration and UDI | EUDAMED actor, UDI/device and certificate registration mandatory since 28 May 2026 (with a transition for devices already on the market) | MHRA device registration before placing on the GB market; UDI not yet required — planned in the pre-market regulations |
| Labelling | CE marking with the notified body number where one is involved; UDI | UKCA mark with the approved body number where one is involved; UKRP name and address on labelling, outer packaging or IFU |
| Post-market surveillance | MDR Articles 83–86: PMS plan, PMCF, PSUR at least every two years (Class IIa) or annually (Class IIb/III); vigilance reported to national authorities | Strengthened GB PMS requirements in force since 16 June 2025; serious incidents reported to the MHRA; apply to CE marked devices in GB too |
| AI-specific rules | EU AI Act high-risk requirements for AI medical devices from 2 August 2028 | No AI-specific device legislation; AI devices are regulated under UK MDR 2002 like other software |
| Recognition in the other market | CE marking recognised in GB — until 30 June 2030 for EU MDR devices under current law; the government intends to make this indefinite | UKCA not recognised in the EU, EEA or Northern Ireland |
3. Software classification and AI — the differences that matter most
Classification of standalone software
EU MDR Rule 11 moved most decision-support and diagnostic software to Class IIa or higher, with a well-developed interpretation framework in MDCG guidance. UK MDR 2002 has no equivalent rule, so the same product can sit in a lower class in GB — often Class I, which can be self-declared under UKCA. The government's October 2026 consultation response confirms that, while GB and EU classification rules are largely aligned, some differences exist; the planned pre-market regulations will change the classification of several device types, but the published documents do not detail changes for software.
If your software sits near a classification boundary, run separate classification analyses under EU MDR Rule 11 and UK MDR 2002 — do not assume the result will be the same. This is part of our regulatory strategy and classification work.
AI and machine learning
Under CE marking, AI-based SaMD must comply with the EU MDR and, for the high-risk requirements, the EU AI Act. After Regulation (EU) 2026/1744, those requirements apply to AI medical devices from 2 August 2028, with a single set of technical documentation assessed by your notified body as part of the MDR conformity assessment. See our EU AI Act guide for medical software.
Under UKCA, AI medical devices are regulated under UK MDR 2002 like other software; there is no UK counterpart to the EU AI Act's binding high-risk requirements. The short-term documentation burden for UKCA is therefore lower — but UK guidance can change without the formal legislative process that applies to EU regulations.
A less prescriptive UK framework for AI does not mean your product can be less rigorously validated. In our experience, approved bodies look for evidence of responsible AI development even where specific documentation is not codified in law, and thin AI validation evidence draws questions in any assessment.
4. Do you need both marks?
Usually not. For the EU and Northern Ireland you need CE marking. For Great Britain you need either CE marking recognised in GB or UKCA — with a UK Responsible Person, MHRA registration and GB post-market surveillance in both cases. Under current law, EU MDR CE marking is recognised in GB until 30 June 2030, and on 21 October 2026 the government announced its intention to recognise EU MDR/IVDR CE marked devices indefinitely; that still needs legislation, which it plans to make before 30 June 2028.
So the question is less "do I need both?" than "is a UK-controlled route worth having?". For most EU-first SaMD companies, CE marking plus the GB obligations is enough. UKCA becomes interesting when your software classifies lower in GB, when the UK is your first market, or when you want a GB route that does not depend on EU certification.
If you pursue both marks, plan for it from the start. Your ISO 13485 QMS, IEC 62304 software life-cycle documentation, risk management and clinical evidence can serve both certifications, with a separate classification analysis, UK approved body assessment and UK-specific labelling and registration on top. Running both processes in parallel rather than one after the other usually saves calendar time.
5. UKCA first: when it makes sense
There are legitimate scenarios where pursuing UKCA before CE marking is the right commercial decision:
- NHS-first go-to-market strategy. If your first customers are NHS trusts or UK private providers and EU expansion comes later, UKCA can allow earlier revenue while your EU MDR technical file matures.
- Lower classification in the UK. Where your software is Class I under UK MDR 2002 but Class IIa or higher under EU MDR Rule 11, UKCA can be a faster path to first market validation while your notified body process proceeds in parallel.
UKCA-only is not a long-term strategy for most companies: the UKCA mark is not recognised in the EU, EEA or Northern Ireland, and the EU remains the larger market for most European SaMD companies.
6. Practical next steps
CE marking (EU MDR)
Plan for long notified body timelines. In the Commission's notified body survey (data as of 28 February 2026), most notified bodies reported 13–18 months from signed written agreement to certificate for combined QMS and product certificates, and a large share reported 19–24 months or more. Our guide to a realistic EU MDR timeline for software breaks this down.
UKCA
For a Class I product under UK MDR 2002, UKCA is a self-declaration — the work is the technical documentation, the UKRP and MHRA registration. For Class IIa and above, the timeline depends on the UK approved body you choose and the completeness of your documentation; ask candidate bodies for their current lead times.
Recommended approach
- Build your QMS to ISO 13485 with both markets in mind from the start — this avoids painful retrofitting later.
- Run classification analyses under both EU MDR Rule 11 and UK MDR 2002 before committing to a conformity assessment route.
- Select your EU notified body (and, if you pursue UKCA, your UK approved body) early — both have application queues.
- Plan EUDAMED registration (EU) and MHRA device registration with your UK Responsible Person (GB) as parallel workstreams.
- If your SaMD uses AI, build your AI Act Annex IV documentation into the technical file from the start — the high-risk requirements apply to AI medical devices from 2 August 2028, and retrofitting takes longer than building in.
UKCA and CE marking now rest on different rules — most visibly for software classification — and the EU does not recognise UKCA. GB, by contrast, recognises CE marking and intends to continue doing so indefinitely, so for many SaMD companies CE marking plus the GB obligations (UKRP, MHRA registration, GB post-market surveillance) is the efficient route. Decide on UKCA deliberately, based on your classification and your market sequence.
- ↗ UK Medical Devices Regulations 2002 (SI 2002/618) — legislation.gov.uk
- ↗ Medical devices: conformity assessment and the UKCA mark — MHRA
- ↗ Regulating medical devices in the UK — MHRA
- ↗ Government response to the consultation on indefinite recognition of CE marked medical devices (October 2026) — UK Government
- ↗ Regulation of medical devices in Northern Ireland — MHRA
- ↗ EU MDR 2017/745 — full text — EUR-Lex